Quarterly ResultAug 6, 2026, 06:38 AM
Zai Lab Q2 Revenue $106.3M; Net Loss $50.8M; Pipeline Advances
AI Summary
Zai Lab Limited announced its second quarter 2026 financial results, reporting total revenues of $106.3 million and a net loss of $50.8 million. Despite a year-over-year revenue decrease, net product revenue grew 11% sequentially. The company highlighted significant pipeline advancements, including multiple Orphan Drug and Fast Track Designations for zocilurtatug pelitecan (zoci), NMPA approval for TIVDAK in China, and the successful commercial launch of KarXT in mainland China. Zai Lab anticipates several key clinical and regulatory milestones in late 2026 and early 2027.
Key Highlights
- Total revenue for Q2 2026 was $106.3 million, a 3.4% decrease from $110.0 million in Q2 2025.
- Net product revenue increased 11% versus the prior quarter.
- Net loss for Q2 2026 was $50.8 million, compared to $40.7 million in Q2 2025.
- Cash and cash equivalents, short-term investments, and current restricted cash totaled $717.5 million as of June 30, 2026.
- Zocilurtatug pelitecan (zoci) received FDA Orphan Drug and Fast Track Designations, and EMA Orphan Drug Designation.
- TIVDAK received NMPA approval in China for recurrent or metastatic cervical cancer.
- KarXT successfully launched in mainland China for the treatment of schizophrenia in adults.
- Multiple registrational studies and clinical data readouts are anticipated in H2 2026 and H1 2027.
Price Impact
More from ZLAB